1. Home
  2. PHAT vs CFFN Comparison

PHAT vs CFFN Comparison

Compare PHAT & CFFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • CFFN
  • Stock Information
  • Founded
  • PHAT 2018
  • CFFN 1893
  • Country
  • PHAT United States
  • CFFN United States
  • Employees
  • PHAT N/A
  • CFFN N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • CFFN Savings Institutions
  • Sector
  • PHAT Health Care
  • CFFN Finance
  • Exchange
  • PHAT Nasdaq
  • CFFN Nasdaq
  • Market Cap
  • PHAT 820.8M
  • CFFN 813.3M
  • IPO Year
  • PHAT 2019
  • CFFN 1999
  • Fundamental
  • Price
  • PHAT $11.66
  • CFFN $6.45
  • Analyst Decision
  • PHAT Strong Buy
  • CFFN Hold
  • Analyst Count
  • PHAT 5
  • CFFN 1
  • Target Price
  • PHAT $16.40
  • CFFN $6.50
  • AVG Volume (30 Days)
  • PHAT 1.1M
  • CFFN 555.8K
  • Earning Date
  • PHAT 11-06-2025
  • CFFN 10-22-2025
  • Dividend Yield
  • PHAT N/A
  • CFFN 5.25%
  • EPS Growth
  • PHAT N/A
  • CFFN N/A
  • EPS
  • PHAT N/A
  • CFFN 0.47
  • Revenue
  • PHAT $114,039,000.00
  • CFFN $192,483,000.00
  • Revenue This Year
  • PHAT $207.52
  • CFFN $10.56
  • Revenue Next Year
  • PHAT $96.46
  • CFFN $11.73
  • P/E Ratio
  • PHAT N/A
  • CFFN $13.78
  • Revenue Growth
  • PHAT 1049.82
  • CFFN N/A
  • 52 Week Low
  • PHAT $2.21
  • CFFN $4.90
  • 52 Week High
  • PHAT $19.71
  • CFFN $7.20
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 54.88
  • CFFN 56.72
  • Support Level
  • PHAT $11.89
  • CFFN $6.34
  • Resistance Level
  • PHAT $13.00
  • CFFN $6.57
  • Average True Range (ATR)
  • PHAT 0.71
  • CFFN 0.11
  • MACD
  • PHAT -0.11
  • CFFN 0.00
  • Stochastic Oscillator
  • PHAT 26.57
  • CFFN 55.13

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

Share on Social Networks: